Induction of cytochrome p450 and peroxisomal enzymes by clofibric acid in vivo and in VITRO
References (22)
- et al.
Complete nucleotide sequence of cDNA and predicted amino acid sequence of rat acyl-CoA oxidase
J Biol Chem
(1987) - et al.
Molecular cloning and nucleotide sequence of the cDNA for rat peroxisomal enoyl-CoA hydratase: 3-hydroxyacyl-CoA dehydrogenase bifunctional enzyme
J Biol Chem
(1985) - et al.
Isolation, complementary DNA sequence, and regulation of rat hepatic lauric acid ω-hydroxylase (cytochrome P-450LAω)
J Biol Chem
(1987) - et al.
Quantitative assessment of enzyme induction by peroxisome proliferators and application to determination of effects on triglyceride biosynthesis in primary cultures of rat hepatocyes
Biochem Pharmacol
(1989) - et al.
Induction of P4502B genes within the rat liver acinus is not dependent on the chemical inducer or on the adnar organisation
J Biol Chem
(1989) Hybridisation of oligo (dT) to RNA on nitrocellulose
Gene Anal Tech
(1987)- et al.
Hypolipidaemic hepatic peroxisome proliferators form a novel class of chemical carcinogens
Nature
(1980) - et al.
Biochemical mechanisms of induction of hepatic peroxisome proliferation
Annu Rev Pharmacol Toxicol
(1989) - et al.
The effect of hypolipidaemic agents on the hepatic microsomal drug-metabolizing enzyme system of the rat
Drug Metab Dispos
(1982) - et al.
Cytochrome P-450 induction by clofibrate
Biochem J
(1982)
The rat clofibrate-inducible CYP4A subfamily II. cDNA sequence of IVA3, mapping of the Cyp4a locus to mouse chromosome 4, and coordinate and tissue-specific regulation of the CYP4A genes
DNA
Cited by (49)
Identification, organ expression and ligand-dependent expression levels of peroxisome proliferator activated receptors in grass carp (Ctenopharyngodon idella)
2012, Comparative Biochemistry and Physiology - C Toxicology and PharmacologyCitation Excerpt :Clofibrate is a widely used PPARα activator with effects on PPAR activation (Bars et al., 1993; Yaacob et al., 2001). Clofibrate at 0.5–1 mM concentration induces synthesis of acyl-CoA oxidase mRNA, a gene in connection with PPRE (Bars et al., 1993). PPARα mRNA in rat primary hepatocytes is increased when exposed to 0.5 mM of clofibrate (Yaacob et al., 2001).
Proteomic mapping of bezafibrate-treated human hepatocytes in primary culture using two-dimensional liquid chromatography
2011, Toxicology LettersCitation Excerpt :Interestingly, the expression of cytochrome P450 4A (CYP4A) was not detected as being affected by BEZA treatment in human hepatocytes. This is in line with previous in vivo and in vitro data showing, in contrast to rats in which PPs strongly induced CYP4A protein, human CYP4A is not induced by PPs (Alvergnas et al., 2009; Bars et al., 1993; Cherkaoui-Malki et al., 2001; Richert et al., 2003; Singleton et al., 1999). As expected according to previous reports by us (Richert et al., 1996; Goll et al., 1999, 2000) and others (Léonard et al., 2006; White et al., 2003), no modification of a peroxisomal protein was evidenced in our analysis in human hepatocytes.
Gestational and lactational exposure to potassium perfluorooctanesulfonate (K<sup>+</sup>PFOS) in rats: Toxicokinetics, thyroid hormone status, and related gene expression
2009, Reproductive ToxicologyCitation Excerpt :Chemicals such as Wyeth 14,643, dexamethasone, and phenobarbital are prototypical agonists used to study activation of PPARα, CAR, and PXR receptors, respectively. Wy14,643 induces hepatomegaly that was characterized by peroxisome proliferation and selective induction of Cyp4a1 and Cyp7a1 [68–70]. Dexamethasone produces hepatomegaly as a consequence of extensive periportal fat accumulation and induction of Cyp3a1 [71,72].
Peroxisomal proliferator-activated receptor-α-dependent inhibition of endothelial cell proliferation and tumorigenesis
2007, Journal of Biological ChemistryCitation Excerpt :In this study, we confirm that Wy-14643, a selective PPRAα ligand, inhibits endothelial cell proliferation and tubulogenesis and, importantly, demonstrate that the functional effects of Wy-14643 are absent in cells from PPARαKO mice and are thus mediated by this nuclear receptor. Because the CYP2C epoxygenases are known PPARα target genes (5–7) and because several reports have characterized the EETs as pro-angiogenic lipids (22–24) and documented the expression of CYP2C epoxygenases in the endothelium (24), we investigated whether the anti-angiogenic effects of Wy-14643 were associated with changes in Cyp2c expression. Three lines of evidence indicate that the anti-angiogenic effects of Wy-14643 result from changes in the expression of Cyp2c epoxygenase isoforms and/or EET levels: (a) phenotype-rescue experiments show that the inhibitory effects of Wy-14643 on endothelial cell proliferation and tubulogenesis can be reversed by the addition of synthetic EETs (Figs. 1 and 3), (b) semi-quantitative RT-PCR analysis of RNAs from endothelial cells cultured in the presence or absence of Wy-14643 showed that the ligand caused marked PPARα-mediated reductions in Cyp2c29, -2c38, and -2c40 epoxygenase transcripts, and (c) Western blots of microsomes from temperature-sensitive immortalized endothelial cells, using anti-Cyp2c44 and anti-CYP2C11 (a rat homologue of murine Cyp2c29, -2c38, and -2c40) antibodies, show that Wy-14643 reduced the cellular levels of anti-CYP2C11 and 2c44 immunoreactive epoxygenase proteins.
- ∗
These authors contributed equally to the contents of the manuscript.